ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2012

Internal Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

9,674Medicare Part D Prescriptions Filled, Including Refills

Rank: 60 out of 393

$486K Total Retail Price of All Prescriptions

Rank: 68 out of 393

708 Patients Receiving at Least One Drug in Part D
76%Patients 65 Years and Older
34% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg Average for
this specialty
in Nevada
Lower avg

Schedule Two
Controlled Substances

11% of this provider’s 708 patients filled at least one prescription for a schedule two drug, compared to an average of 7%.

Schedule Three
Controlled Substances

17% of this provider’s 708 patients filled at least one prescription for a schedule three drug, compared to an average of 14%.

Risky Drugs to Seniors

1% of this provider’s 7,061 prescriptions for patients 65 and older were for "potentially dangerous" drugs, compared to an average of 1%.

Brand Name Drugs

14% of this provider’s prescriptions were for brand-name drugs, compared to an average of 23%.

Prescription Price

$50 was the average price of a prescription from this provider, compared to $54 among peers.

Prescriptions per Patient

14 is the average number of prescriptions (including refills) per patient, compared to an average of 15.


Another View

This chart shows a different comparison of all providers in this specialty based on their mix of drugs and volume. Providers are grouped by similarity; those least like their peers are farthest to the right. Hover over the bars to see names of other prescribers.

← Prescribers more like their peers Prescribers less like their peers →
KEY: How to read this
chart

Fewer Prescribers
More Prescribers

This Prescriber
Hover to see more prescribers

This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled
Including Refills
Prescriptions
to 65+
Category For this Prescriber For All Prescribers in
This Specialty in Nevada
HYDROCODONE-ACETAMINOPHEN 677 406 S3 1 5
LISINOPRIL 455 378 2 2
FLUTICASONE PROPIONATE 382 288 3 27
LEVOTHYROXINE SODIUM 295 236 4 3
SIMVASTATIN 281 243 5 1
MELOXICAM 250 183 6 58
PREDNISONE 228 181 7 65
OMEPRAZOLE 221 163 8 6
ATENOLOL 207 151 9 13
METFORMIN HCL 204 170 10 7
ZOLPIDEM TARTRATE 186 135 11 11
LOVASTATIN 168 149 12 14
METOPROLOL TARTRATE 164 140 13 9
PRAVASTATIN SODIUM 160 123 14 18
GABAPENTIN 156 121 15 15
AMLODIPINE BESYLATE 155 129 16 4
OXYCODONE HCL 154 60 S2 17 36
CARISOPRODOL 145 16 R 18 45
DOXAZOSIN MESYLATE 132 118 19 83
HYDROCHLOROTHIAZIDE 117 96 20 10
LISINOPRIL-HYDROCHLOROTHIAZIDE 116 97 21 24
OXYCODONE HCL-ACETAMINOPHEN 114 63 S2 22 54
CARVEDILOL 101 93 23 21
CIPROFLOXACIN HCL 100 74 24 57
WARFARIN SODIUM 95 82 25 17
AZITHROMYCIN 90 70 26 35
GLIPIZIDE 90 73 26 32
FINASTERIDE 89 77 28 60
FUROSEMIDE 89 81 28 8
LOSARTAN POTASSIUM 85 69 30 12
TERAZOSIN HCL 83 64 31 38
ALLOPURINOL 83 62 31 26
FLUOXETINE HCL 70 49 33 37
CLONIDINE HCL 70 47 33 50
MORPHINE SULFATE ER 64 17 S2 35 48
SERTRALINE HCL 63 37 36 28
IBUPROFEN 62 24 37 55
CITALOPRAM HBR 61 34 38 23
POTASSIUM CHLORIDE 60 45 39 20
RANITIDINE HCL 60 44 39 29
TRAZODONE HCL 54 25 41 47
LANTUS SOLOSTAR 51 36 42 74
VENTOLIN HFA 51 30 42 42
About This Data

ProPublica obtained prescribing data from Medicare’s prescription drug benefit, known as Part D, under the Freedom of Information Act. The data for 2012 includes more than 1.2 billion prescriptions written by nearly 1.5 million doctors, nurses and other providers. This database lists about 382,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths went to patients 65 and older; the rest were for disabled patients. Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to drugs@propublica.org and we will update your information. If you have other questions about this data, send a note to drugs@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • The calculation of “Risky Drugs to Seniors” does not include drugs for which a provider wrote 11 or fewer prescriptions because Medicare redacted the information to protect patient privacy.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Jan. 26, 2012.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.